Actionable news
All posts from Actionable news
Actionable news in TTPH: Tetraphase Pharmaceuticals, Inc.,

Tetraphase Pharmaceuticals, Inc. (TTPH)


    "Eravacycline, an experimental agent synthesized from tetracycline, is undergoing Phase III efficacy trials against complicated intra-abdominal infection and urinary tract infection, and may be effective against gonorrhea as well, reports The Pharma Letter’s correspondent at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, USA."

  • On June 14, 2017, Tetraphase Pharmaceuticals, Inc. (the “Company”) and Patheon UK Limited and certain of its affiliates (collectively, “Patheon”) entered into a Master Manufacturing Services Agreement (the “Master Agreement”). Under the Master Agreement, the Company is responsible for supplying the active pharmaceutical ingredient for eravacycline to Patheon, and Patheon is responsible for manufacturing eravacycline, conducting quality control, quality assurance, analytical testing and stability testing and packaging.
    The Company expects to enter into two related Product Agreements (each a “Product Agreement”) pursuant to the Master Agreement to govern the terms and conditions of Patheon’s manufacture of commercial supplies of eravacycline, the Company’s lead...